Lidds AB Cash Flow Conversion Efficiency
Lidds AB cash flow conversion efficiency. Based on the latest financial reports, Lidds AB (LIDDS) has a cash flow conversion efficiency ratio of -0.413x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-616.00K ≈ $-66.29K USD) by net assets (Skr1.49 Million ≈ $160.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lidds AB (2013–2024)
Cash flow conversion efficiency of Lidds AB from 2013 to 2024. This chart illustrates how Lidds AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LIDDS stock price and chart for real-time trading data and today's change.
Lidds AB Cash Flow Conversion Ratio Explained
Lidds AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lidds AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lidds AB ranked by their cash flow conversion efficiency. Also see how much is Lidds AB worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SysGroup PLC
LSE:SYS
|
0.029x |
|
MEDCAW INVESTMENTS LS-01
F:U09
|
N/A |
|
Wildpack Beverage Inc
V:CANS
|
0.068x |
|
Israel Opportunity - Energy Resources LP
TA:ISOP-L
|
-0.055x |
|
Helium One Global Ltd
LSE:HE1
|
-0.001x |
|
KOYJ Co. Ltd
KQ:121850
|
-1.361x |
|
BLUERUSH Media Group Corp
V:BTV
|
-0.015x |
|
Imobiliária Construtora Grão Pará S.A.
LS:GPA
|
0.000x |
Annual Cash Flow Conversion Efficiency for Lidds AB (2013–2024)
The table below shows the annual cash flow conversion efficiency of Lidds AB from 2013 to 2024. Review Lidds AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr6.18 Million ≈ $664.96K |
Skr-5.43 Million ≈ $-584.68K |
-0.879x | +53.39% |
| 2023-12-31 | Skr13.90 Million ≈ $1.50 Million |
Skr-26.22 Million ≈ $-2.82 Million |
-1.886x | +18.65% |
| 2022-12-31 | Skr15.35 Million ≈ $1.65 Million |
Skr-35.59 Million ≈ $-3.83 Million |
-2.319x | -163.81% |
| 2021-12-31 | Skr48.51 Million ≈ $5.22 Million |
Skr-42.64 Million ≈ $-4.59 Million |
-0.879x | -37.23% |
| 2020-12-31 | Skr42.81 Million ≈ $4.61 Million |
Skr-27.42 Million ≈ $-2.95 Million |
-0.641x | -470.12% |
| 2019-12-31 | Skr152.13 Million ≈ $16.37 Million |
Skr-17.09 Million ≈ $-1.84 Million |
-0.112x | -1131.42% |
| 2018-12-31 | Skr158.52 Million ≈ $17.06 Million |
Skr-1.45 Million ≈ $-155.64K |
-0.009x | +89.16% |
| 2017-12-31 | Skr127.25 Million ≈ $13.69 Million |
Skr-10.71 Million ≈ $-1.15 Million |
-0.084x | -352.72% |
| 2016-12-31 | Skr112.52 Million ≈ $12.11 Million |
Skr-2.09 Million ≈ $-225.21K |
-0.019x | +74.68% |
| 2015-12-31 | Skr99.77 Million ≈ $10.74 Million |
Skr-7.33 Million ≈ $-788.75K |
-0.073x | -3.47% |
| 2014-12-31 | Skr96.37 Million ≈ $10.37 Million |
Skr-6.84 Million ≈ $-736.33K |
-0.071x | -1.37% |
| 2013-12-31 | Skr75.21 Million ≈ $8.09 Million |
Skr-5.27 Million ≈ $-566.87K |
-0.070x | -- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more